Abstract Aim Perianal sepsis in Crohn's disease (CD) fistulas is managed with antibiotics
and surgical drainage; a noncutting seton is used for an identified transsphincteric fistula …

Purpose We assessed the clinical outcomes of a seton procedure combined with early
versus late institution of infliximab (IFX) therapy. Methods This retrospective study comprised …

Results For all patients average number of inserted drains was 4.5 and the average number
of infliximab infusions was 9.4 times. The mean follow-up period was 12.1 months. A …

Abstract Background and Aims Most patients with perianal Crohn's fistula receive medical
treatment with anti-tumour necrosis factor [TNF], but the results of anti-TNF treatment have …

Aim Around one‐third of patients with Crohn's disease are affected by Crohn's fistula‐in‐ano
(p CD). It typically follows a chronic course and patients undergo long‐term medical and …

Background Currently there is no guideline for the treatment of patients with Crohn's disease
and high perianal fistulas. Most patients receive anti-TNF medication, but no long-term …

Summary Background Treatment paradigms for Crohn′ s disease with perianal fistulae
(CD‐pAF) are evolving. Aims To study the impact of multimodality treatment in CD‐pAF on …

Aim The introduction of anti‐tumour necrosis factor (anti‐TNF; infliximab and adalimumab)
has changed the management of Crohn's perianal fistula from almost exclusively surgical …

Aim Combined infliximab and sphincter‐sparing surgery can be effective in perianal fistula
associated with Crohn's disease (CD). This study aimed to assess the efficacy of local …

Objective This study was designed to assess the demographic characteristics of patients
with Crohn's perianal fistula (CPF) who were treated at a tertiary referral institution. Surgical …